Two-year treatment outcomes of patients enrolled in India's national first-line antiretroviral therapy programme

National Medical Journal of India

Volumn 23, Issue 1, 2010, Pages 7-12

  Bachani, Damodar ^a   Garg, Renu ^b   Rewari, Bharat B ^b   Hegg, Lea ^c   Rajasekaran, Sikhamani ^d   Deshpande, Alaka ^e   Emmanuel, K V ^f   Chan, Polin ^b   Rao, K Sujatha ^a  

^a GOVERNMENT OF INDIA   (India)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d General Hospital for Thoracic Medicine ^*  (India)

^e SIR J J GROUP OF HOSPITALS   (India)

^f OSMANIA MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; FEMALE; GASTROINTESTINAL DISEASE; HEALTH PROGRAM; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; ACQUIRED IMMUNODEFICIENCY SYNDROME; COHORT ANALYSIS; IMMUNOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PUBLIC HEALTH; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77950532042     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: An effectiveness assessment. Lancet 2006;367:1335-42.
2. Marins JR, Jamal LF, Chen SY, Barros MB, Hudes ES, Barbosa AA, et al. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS 2003;17: 1675-82.
3. Stringer JSA, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale- up of antiretroviral therapy at primary care sites in Zambia: Feasibility and early outcomes. JAMA 2006;296:782-93.
4. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: Patients' response, survival, and drug resistance. Lancet 2002;360:34-40.
5. Kebba A, Atwine D, Mwebaze R, Kityo C, Nakityo R, Mulenyi P. Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients. AIDS Res Hum Retroviruses 2002;18:1181-7.
6. Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005;353:2325-34.
7. Kober K, Van Damme W. Scaling up access to antiretroviral treatment in southern Africa: Who will do the job? Lancet 2004;364:103-7.
8. Ojikutu B, Jack C, Ramjee G. Provision of antiretroviral therapy in South Africa: Unique challenges and remaining obstacles. J Infect Dis 2007;196:S523-S527.
9. Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT. Antiretroviral therapy- associated toxicities in the resource-poor world: The challenges of a limited formulary. J Infect Dis 2007;196 (Suppl 3):S449-S456.
10. Spacek LA, Shihab HM, Kamya MR, Mwesigire D, Ronald A, Mayanja H, et al. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis 2006;42:252-9.
11. UNAIDS/WHO. AIDS Epidemic update. December 2007. Geneva: UNAIDS/ WHO; 2007.
12. National AIDS Control Organization of India. HIV data. Available from http://www.nacoonline.org/Quick_links/HIV_Data (accessed on 22 February 2010).
13. Kumarasamy N, Solomon S, Chaguturu SK, Mahajan AP, Flanigan TP, Balakrishnan P, et al. The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS 2003;17:2267-9.
14. Kumarasamy N, Venkatesh KK, Devaleenol B, Poongulali S, Mothi SN, Solomon S. Safety, tolerability and effectiveness of generic HAART in HIV-infected children in South India. J Trop Pediatr 2009;55:155-9.
15. Kumarasamy N, Venkatesh KK, Cecelia AJ, Devaleenal B, Lai AR, Saghayam S, et al. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDs 2008;4:337-44.
16. Pujari SN, Patel AK, Naik E, Patel KK, Dravid A, Patel JK, et al. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immune Defic Syndr 2004;37:1566-9.
17. Pujari S, Dravid A, Gupte N, Joshi K, Bele V. Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India. Medscape J Med 2008;10:196.
18. Patel A, Patel K, Patel J, Shah N, Patel B, Rani S. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1. J Acquir Immune Defic Syndr 2004;37:1166-9.
19. Sharma A, Wanchu A, Bansal V, Singh S, Varma S. Improvement in CD 4 counts in HIV positive patients treated with HAART and antitubercular drugs: An observational study from North India. Indian J Pathol Microbiol 2007;50:905-7.
20. National AIDS Control Organization of India. Antiretroviral therapy guidelines for HIV-infected adults and adolescents including post-exposure prophylaxis. NACO 2007. Available at http//:www.whoindia.org/EN/Section3/Section125_1499.htm (accessed on 1 April 2008).
21. The antiretroviral therapy in lower income countries (ART-Linc) collaboration; ART cohort collaboration (ART-CC) groups. Mortality of HIV-1 infected patients in the first year of antiretroviral therapy: Comparison between low-income and highincome countries. Lancet 2006;367:817-24.
22. The Antiretroviral Therapy (ART) Cohort Collaboration. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: A collaborative analysis. Lancet 2006;368:451-8.
23. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: A collaborative analyses of prospective studies. Lancet 2002;360:119-29.
24. Zhou J, Kumarasamy N. Predicting short-term disease progression among HIVinfected patients in Asia and the Pacific region: Preliminary results from the TREAT Asia HIV observational database (TAHOD). HIV Medicine 2005;6:215-23.
25. Government of India. Third National Health and Family Survey. GOI 2006.
26. National AIDS Control Organization. State-wise list of integrated counseling and testing centres. Available at http://www.nacoonline.org (accessed on 22 February 2010).
27. Bedelu M, Ford N, Hilderbrand K, Reuter H. Implementing antiretroviral therapy in rural communities: The Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis 2007;196:S464-S468.
28. Karcher H, Omondi A, Odera J, Kunz A, Harms G. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health 2007;12:687-94.
29. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS [Research Letters]. AIDS 2001;15:1181-3.
30. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
31. Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load: A meta analytic review of randomized controlled trials. J Acquir Immune Defic Syndr 2006;43:S23-S35.
32. Shah B, Walshe L, Saple DG, Mehta SH, Ramnani JP, Kharkar RD, et al. Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India. Clin Infect Dis 2007;44:1235-44.
33. Kumarasamy N, Safren SA, Raminani SR, Pickard R, James R, Krishnan AKS, et al. Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: A qualitative study. AIDS Patient Care STDs 2005;19: 526-37.
34. Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, Schouten EJ, et al. True outcomes for patients on antiretroviral therapy who are 'lost to follow-up' in Malawi. Bull World Health Organ 2007;85:550-4.
35. National AIDS Control Organization of India. Operational guidelines for antiretroviral treatment centres. NACO 2007. Available at http//:www.whoindia.org/EN/Section3/Section125_1499.htm (accessed on 1 April 2008).